AI, digital health or biotech component: Is a start-up investable without?

The boundaries between MedTech, biotech, and digital health are becoming increasingly blurred, with more investors looking at interdisciplinary opportunities. Data also shows the undeniable popularity of investment in AI and digital health, while pure MedTech investors are becoming rare. Does it mean that start-ups need a biotech, digital health or artificial intelligence component to be investable nowadays? What types of convergence are investors eyeing? How are investors weighing the risks and analysing the potential for significant returns? Where does pure MedTech investment position itself?